NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Assessment of Blood Tumor Mutational Burden as a Biomarker for Immunotherapy in NSCLC With Use of a Cancer Gene Panel

The authors of this study of two independent cohorts of patients with advanced NSCLC found that the cancer gene panel NCC-GP150 was cost-effective, with a satisfactory performance, for estimation of tumor mutational burden. The blood tumor mutational burden estimated by NCC-GP150 correlated well with the tissue tumor mutational burden calculated by whole-exome sequencing, and a blood tumor mutational burden of ≥6 was positively associated with clinical benefits of anti–PD-1 and anti–PD-L1 therapy in patients with advanced NSCLC.

Blood tumor mutational burden measured by NCC-GP150 is a potential biomarker to identify patients with NSCLC who could benefit from anti–PD-1 and anti–PD-L1 therapy.


https://www.practiceupdate.com/c/80437/2/1/